

## Special Issue

# Molecular Mechanisms and Clinical Implications of Pancreatic Cancer

### Message from the Guest Editor

Pancreatic cancer is one of the most lethal malignancies. Despite significant progress in other cancers, pancreatic cancer survival rates have remained relatively unchanged for 40 years. New approaches are critical to successfully diagnosing and treating this disease. Due to the recent progress in comprehensive analysis using next-generation sequencing, we have deeply understood the molecular characteristics of pancreatic cancer, including genetic and epigenetic alterations. These alterations are potent biomarkers for diagnosis and predicting therapeutic outcomes for pancreatic cancer patients. The real-time monitoring of these alterations is realized by the use of liquid biopsy and has been implemented into clinical practice. This Special Issue focuses on the biomarkers underlying the molecular biology of pancreatic cancer and discusses how to implicate them into clinical practice. Original research articles and reviews are welcome. We look forward to receiving your contributions.

### Guest Editor

Dr. Koichi Suzuki

Department of Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi 330-8503, Saitama, Japan

### Deadline for manuscript submissions

closed (1 September 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/164667](https://mdpi.com/si/164667)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)